Lupus Anticoagulant in Drug-Induced Systemic Lupus Erythematosus (SLE)-Reply

Neurobrucellosis in systemic lupus erythematosus

Background: Brucellosis is a zoonotic infection which is endemic in many countries. It is a multisystem disease which may present with a broad spectrum of clinical manifestations and complications. Neurobrucellosis is an uncommon complication of brucellosis. Case presentation: A 25-year-old woman with a history of lupus for 5 months referred to the emergency ward of Shahid Beheshti Hosp...

Lupus (Systemic Lupus Erythematosus; SLE) — Diagnosis and Treatment

Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE) †

A number of monoclonal antibodies (mAb) are now under investigation in clinical trials to assess their potential role in Systemic Lupus Erythematosus (SLE). The most frequently used mAb is rituximab, which is directed against CD20, a membrane protein expressed on B lymphocytes. Uncontrolled trials reported an improvement of SLE activity in non-renal patients and other studies even reported an i...

Lupus anticoagulant, anticardiolipin antibodies, fetal loss, and systemic lupus erythematosus.

UPUS ANTICOAGULANTS (LA) and anticardioL lipin (ACL) antibodies (ACLA) belong to a heterogenous group of antibodies directed against negatively charged pho~pholipids.l-~ However, more recent studies would suggest that these antibodies are directed to epitopes of other proteins that are complexed with negatively charged phospholipid~>-~ Although antiphospholipid antibodies are frequently found i...

Oral manifestations and its associated factors in Iranian Systemic lupus erythematosus (SLE) patients

Background and Objective: Due to the overall wide range of oral manifestations and the lack of comprehensive categorized information in Iran, this study was performed to investigate the prevalence of different oral manifestations and report their possible associated factors in patients with SLE. Materials and Methods: This cross-sectional study was performed on 96 SLE patients referred to two ...